Several of the proteins identified in our study have been reported previously to be elevated in HER2+ BC and TNBC, suggesting that the GeLC-MS/MS methodology is a powerful screening tool for the identification of novel biomarkers for aggressive subtypes of BC. This evidence concerns the gene ERBB2 and breast cancer.